Dong-A likely to commercialize new second-generation oxazolidinone antibiotic

Published: 2012-01-25 06:58:00

Updated: 2012-01-25 06:58:00

Dong-A Pharmaceutical Co. announced Thursday the positive results of its new second-generation oxazolidinone antibiotic (tedizolid phosphate; DA-7218) from the first Phase 3 clinical trial in acute bacterial skin and skin structure infections, heralding the possible development of a global new dr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK